Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion
| Autor: | Jia Shen, A. Simon Turner, Emily A. Berthiaume, Soonchul Lee, Janette N. Zara, Chenchao Wang, Hsin Chuan Pan, Howard B. Seim, Xinli Zhang, Kang Ting, Alan Nguyen, Jin Hee Kwak, Chia Soo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pathology
medicine.medical_specialty Bone density medicine.medical_treatment Bone Morphogenetic Protein 2 Lumbar vertebrae Bone morphogenetic protein Bone morphogenetic protein 2 Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Bone Density Osteogenesis Transforming Growth Factor beta medicine Animals Humans Cyst 030212 general & internal medicine Bone mineral Lumbar Vertebrae Sheep business.industry Regular Article medicine.disease Recombinant Proteins Spinal Fusion medicine.anatomical_structure Spinal fusion Models Animal Female Implant Tomography X-Ray Computed business 030217 neurology & neurosurgery |
| Zdroj: | The American Journal of Pathology. 187:1485-1495 |
| ISSN: | 0002-9440 |
| Popis: | Multiple case reports using recombinant human bone morphogenetic protein-2 (rhBMP-2) have reported complications. However, the local adverse effects of rhBMP-2 application are not well documented. In this report we show that, in addition to promoting lumbar spinal fusion through potent osteogenic effects, rhBMP-2 augmentation promotes local cyst-like osteolytic formations in sheep trabecular bones that have undergone anterior lumbar interbody fusion. Three months after operation, conventional computed tomography showed that the trabecular bones of the rhBMP-2 application groups could fuse, whereas no fusion was observed in the control group. Micro–computed tomography analysis revealed that the core implant area's bone volume fraction and bone mineral density increased proportionately with rhBMP-2 dose. Multiple cyst-like bone voids were observed in peri-implant areas when using rhBMP-2 applications, and these sites showed significant bone mineral density decreases in relation to the unaffected regions. Biomechanically, these areas decreased in strength by 32% in comparison with noncystic areas. Histologically, rhBMP-2–affected void sites had an increased amount of fatty marrow, thinner trabecular bones, and significantly more adiponectin- and cathepsin K-positive cells. Despite promoting successful fusion, rhBMP-2 use in clinical applications may result in local adverse structural alterations and compromised biomechanical changes to the bone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|